"Genetic Test Identifies Best Antidepressant" - Megan Brooks
Patients with major depressive disorder (MDD) in whom initial antidepressant therapy fails do better the next time around if their medication selection is guided by pharmacogenomic testing, according to results of the largest-ever pharmacogenomics clinical study in depression. The study was presented at the American Psychiatric Association 2018 Annual Meeting. James Murrough, MD, assistant professor of psychiatry and neuroscience and director of the mood and anxiety disorders program at the Icahn School of Medicine at Mount Sinai, said the findings are exciting. “The use of genetic testing to help determine antidepressant treatment for patients is something that the field has been working towards for a long time. It is not considered standard of care currently, so this study really adds significantly to the field and may make a real impact on clinical care,” said Dr. Murrough.
- James Murrough, MD, Assistant Professor, Psychiatry, Neuroscience, Director, Mood and Anxiety Disorders Program, Icahn School of Medicine at Mount Sinai